Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Long-Term Deferred Tax (2016 - 2025)

Ani Pharmaceuticals' Long-Term Deferred Tax history spans 12 years, with the latest figure at $69.1 million for Q4 2025.

  • For Q4 2025, Long-Term Deferred Tax fell 18.84% year-over-year to $69.1 million; the TTM value through Dec 2025 reached $69.1 million, down 18.84%, while the annual FY2025 figure was $69.1 million, 18.84% down from the prior year.
  • Long-Term Deferred Tax for Q4 2025 was $69.1 million at Ani Pharmaceuticals, down from $71.4 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $92.0 million in Q2 2025 and bottomed at $52.0 million in Q1 2021.
  • The 5-year median for Long-Term Deferred Tax is $79.1 million (2022), against an average of $76.8 million.
  • The largest annual shift saw Long-Term Deferred Tax surged 41.4% in 2022 before it fell 19.82% in 2024.
  • A 5-year view of Long-Term Deferred Tax shows it stood at $67.9 million in 2021, then grew by 19.76% to $81.4 million in 2022, then grew by 11.49% to $90.7 million in 2023, then decreased by 6.18% to $85.1 million in 2024, then dropped by 18.84% to $69.1 million in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Long-Term Deferred Tax are $69.1 million (Q4 2025), $71.4 million (Q3 2025), and $92.0 million (Q2 2025).